Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

June 2022

Real-world population-based study shows that a switch to a second JAKinib results in a higher drug retention, as compared to switching to a TNFi, in patients with RA who discontinue original JAKinib therapy.

Keywords: